Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2017 April;108(2) > Minerva Medica 2017 April;108(2):176-84

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

MINERVA MEDICA

Rivista di Medicina Interna


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,878


eTOC

 

REVIEW  


Minerva Medica 2017 April;108(2):176-84

DOI: 10.23736/S0026-4806.16.04571-7

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Association of HLA-DRB1 gene polymorphisms with hepatocellular carcinoma risk: a meta-analysis

Li LIU 1, Wuhua GUO 1, Jixiang ZHANG 1, 2

1 The Second Affiliated Hospital of Nanchang University, Nanchang, China; 2 Jiangxi Province Key Laboratory of Molecular Medicine, Nanchang, China


PDF  


INTRODUCTION: The study aimed to assess the association between human leukocyte antigen (HLA)-DRB1 allele polymorphisms and hepatocellular carcinoma (HCC) susceptibility.
EVIDENCE ACQUISITION: Relevant case-control studies on HLA-DRB1 allele correlation with HCC risk published between 2000 and 2015 were searched and retrieved in literature database. The odds ratio (OR) with its 95% confidence interval (CI) were employed to calculate the strength of association. Total 16 articles including 2208 HCC patients and 3028 relevant controls were finally screened out.
EVIDENCE SYNTHESIS: A total of 12 case-control studies including 2030 HCC patients and 2817 relevant controls were screened out. Thirteen alleles (HLA-DRB1 *01, *03, *04, *07, *08, *09, *10, *11, *12, *13, *14, *15, and *16) were reported. Overall, we found that HLA-DRB1 *1 and *11 allele polymorphisms were significantly associated with decreased the HCC risk (*1: OR=0.53, 95% CI: 0.29-0.96, P=0.04; *11: OR=0.58, 95% CI: 0.38-0.88, P=0.010); while *12 and *14 allele polymorphisms were significantly associated with increased the HCC risk (*12: OR=1.49, 95% CI: 1.08-2.07, P=0.02; *14: OR=1.89, 95% CI: 1.27-2.82, P=0.002) in a fixed-effect model. However, other HLA-DRB1 allele polymorphisms were not associated with HCC susceptibility (P>0.05).
CONCLUSIONS: HLA-DRB1 *1 and *11 allele polymorphisms were protective factors, *12 and *14 allele polymorphisms were risk factors for HCC development. Future large-scale studies with more ethnicities are still needed.


KEY WORDS: Carcinoma, hepatocellular - HLA-DRB1 chains - Alleles - Meta-analysis

inizio pagina

Publication History

Issue published online: February 20, 2017
Article first published online: November 3, 2016
Manuscript accepted: October 19, 2016
Manuscript revised: October 13, 2016
Manuscript received: June 7, 2016

Per citare questo articolo

Liu L, Guo W, Zhang J. Association of HLA-DRB1 gene polymorphisms with hepatocellular carcinoma risk: a meta-analysis. Minerva Med 2017;108:176-84. DOI: 10.23736/S0026-4806.16.04571-7

Corresponding author e-mail

jxzhang3@163.com